Leqvio and Pregabalin Interaction: What Clinicians and Patients Should Know

Two different drug classes, disambiguated

Inclisiran (Leqvio) is a triantennary N-acetylgalactosamine (GalNAc)-conjugated synthetic double-stranded small interfering RNA (siRNA) that received FDA approval for use alongside diet and maximal statin therapy in adults with established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia requiring additional LDL cholesterol reduction. The medication is delivered via subcutaneous injection using a dosing schedule of an initial injection, a second dose at three months, followed by maintenance doses every six months.

Pregabalin (brand name Lyrica, also available generically) is a small-molecule gabapentinoid that binds the alpha-2-delta subunit of voltage-gated calcium channels. It is FDA-approved for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, fibromyalgia, and as adjunctive therapy for partial-onset seizures, and it is taken orally, typically one to three times daily.

These two drugs do not belong to overlapping classes, are not prescribed for the same indication, and are structurally and mechanistically unrelated. The question clinicians and patients actually need answered is narrower than "do they interact": it is whether inclisiran's liver-restricted siRNA mechanism can plausibly touch pregabalin's renal, CNS-directed disposition at any point. It cannot, based on the mechanistic evidence below.

Why inclisiran avoids the usual interaction checkpoints

Inclisiran is taken up specifically by hepatocytes through the asialoglycoprotein receptor, then binds the RNA-induced silencing complex (RISC) intracellularly to trigger cleavage of PCSK9 messenger RNA. The intact siRNA molecule is subsequently broken down by endogenous nucleases into inactive nucleotide fragments. It never enters systemic metabolic pathways that would put it in contact with cytochrome P450 enzymes or common drug transporters.

The FDA prescribing information for Leqvio states that inclisiran is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes or drug transporters, and the European Medicines Agency's summary of product characteristics for Leqvio reaches the same conclusion (FDA label; EMA SmPC). This is a labeled, regulator-reviewed statement about the drug's own metabolic profile, not a study of the inclisiran-pregabalin pair specifically. Because no CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, P-glycoprotein, OATP1B1/1B3, or BCRP involvement exists, the standard pharmacist interaction checkpoints for inclisiran return no flags for essentially any oral small molecule, pregabalin included.

Clinical trials of the ORION inclisiran program enrolled patients on typical cardiovascular polypharmacy, including statins, antiplatelet agents, and antihypertensives, and the FDA label does not list any co-administered drug class that altered inclisiran's efficacy or safety profile. Exact effect sizes and adverse-event rates from those trials are not reproduced here because the discovery process for this article could not confirm a verified primary-source link for the specific figures; a clinician who needs precise numbers should pull them directly from the FDA label or the published trial reports rather than relying on a secondary summary.

Why pregabalin avoids the usual interaction checkpoints

Pregabalin has an unusually simple pharmacokinetic profile. Oral bioavailability exceeds 90% and is not affected by food. Roughly 98% of an oral dose is recovered unchanged in urine, meaning hepatic metabolism plays essentially no role in its elimination. Plasma protein binding is negligible, well under 1%. The FDA label for Lyrica states that pregabalin does not inhibit the major CYP450 isoforms and is not a substrate for hepatic transporters. Renal clearance, governed by glomerular filtration rate, drives essentially all of pregabalin's disposition.

This matters for the interaction question because any drug capable of interacting with pregabalin would need to alter renal blood flow, tubular handling, or CNS calcium-channel activity. Inclisiran does none of these things: it is not renally cleared, does not affect glomerular filtration, and does not cross into the CNS.

Evidence-status interaction assessment

Rather than a single verdict, the honest way to describe this pairing is by evidence tier. This table separates what each drug's own labeling establishes from what remains inference, and flags what a prescriber or pharmacist should still verify before treating the combination as risk-free in an individual patient.

What this means in practice: a pharmacist running an automated interaction check will correctly return "no interaction" because the mechanistic checkpoints are clean, not because a dedicated safety study confirmed it. That distinction rarely matters for a healthy adult on both drugs, but it does matter for edge cases such as severe renal or hepatic impairment, where the absence of a specific study should be disclosed to the patient rather than glossed over.

What could look like an interaction but isn't

Two clinical scenarios can create the appearance of an interaction where none exists.

Myalgia confusion. Patients starting inclisiran alongside a background statin sometimes attribute any new muscle symptom to the "cholesterol injection." If pregabalin was started or increased around the same time, the temporal overlap can create diagnostic confusion, since gabapentinoids are associated with peripheral edema in a meaningful minority of patients at higher doses. A careful history distinguishing statin-associated myopathy from pregabalin-related edema, rather than assuming either drug is at fault by default, resolves this.

CNS symptom confusion. Pregabalin's labeled adverse effects include dizziness and somnolence in a substantial proportion of trial participants. Because inclisiran does not cross the blood-brain barrier and has no CNS pharmacology, any new cognitive or sedative complaint in a patient on both drugs should be worked up as pregabalin-related (or related to another CNS-active co-prescription such as an opioid or benzodiazepine), not as an inclisiran effect.

Monitoring: what to check, and what not to over-check

No combined monitoring protocol is needed for this pairing. Each drug is monitored on its own schedule.

For inclisiran, LDL cholesterol is typically rechecked in the weeks following the initial dose and periodically thereafter to confirm response, consistent with standard practice for any lipid-lowering therapy adjustment. Liver enzyme monitoring is not specifically required by the FDA label.

For pregabalin, monitoring should focus on renal function, since dose adjustment is required as creatinine clearance falls below defined thresholds, along with routine assessment for dizziness, somnolence, peripheral edema, mood changes, and signs of misuse, particularly in patients with a substance use history. The FDA label for Lyrica addresses dose reduction in renal impairment directly; a clinician managing a patient with declining kidney function should consult the label's dosing table rather than relying on a generalized rule of thumb, since exact cutoffs and reduced-dose ranges are specific and worth confirming at the point of prescribing.

Special populations

Renal impairment. Pregabalin dosing must be reduced as creatinine clearance declines; the FDA label specifies stepped dose reductions at defined thresholds. Inclisiran's label does not include a renal dose adjustment for mild to moderate impairment; data in severe renal impairment are more limited, and prescribers should check the current label before relying on this for a patient with advanced kidney disease.

Hepatic impairment. Pregabalin's disposition is unaffected by liver function because it bypasses hepatic metabolism almost entirely. Inclisiran acts inside hepatocytes, and its label recommends caution in severe hepatic impairment because that population has not been well studied. This is a caution about inclisiran's own use in that population, not a caution specific to combining it with pregabalin.

Older adults. Age itself does not introduce a new interaction pathway between these drugs. Pregabalin clearance falls in proportion to age-related decline in kidney function, which should be reflected in dosing regardless of inclisiran use.

The evidence boundary, stated plainly

What is established: neither drug is metabolized by CYP450 enzymes, neither is a substrate or inhibitor of the drug transporters the other might otherwise depend on, and their pharmacodynamic targets (hepatocyte PCSK9 mRNA versus CNS calcium channels) do not overlap. This is documented in each drug's own FDA prescribing information and, for inclisiran, in the EMA product information.

What is plausible but not directly tested: that this mechanistic independence holds up identically in patients with severe renal or hepatic impairment, or in patients on many additional interacting CNS or hepatic-clearance drugs simultaneously. Mechanistic reasoning suggests no problem, but a dedicated interaction study in these subgroups has not been identified.

What is not established: any dedicated clinical trial or pharmacovigilance signal specifically testing inclisiran co-administered with pregabalin. The absence of a signal in major interaction databases and in each drug's individual trial program is reassuring but is not the same as a study designed to detect a rare or population-specific interaction.

How to counsel a patient asking about this combination

A patient asking whether Leqvio and pregabalin can be taken together can be told plainly: these two medications work through completely separate biological systems, do not interfere with each other's absorption or metabolism, and require no timing separation, since inclisiran is given as an in-office injection every six months while pregabalin is taken orally at home. Side effects from one drug should not be assumed to be caused by the other, and any new symptom, whether a muscle ache, dizziness, or swelling, is worth reporting to the prescriber rather than self-diagnosing based on which drug seems newer or more unusual.

Patients with reduced kidney function should make sure every prescriber, including whoever manages the pregabalin, knows their current renal function, since pregabalin dosing depends directly on it while inclisiran dosing generally does not. When a symptom is new, persistent, severe, or accompanied by signs such as swelling of the face or throat, difficulty breathing, chest pain, or significant confusion, urgent evaluation is appropriate regardless of which drug is suspected.